PALI
Palisade Bio, Inc. [PALI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PALI Stock Summary
Top 10 Correlated Stocks
PALI
In the News
PALI Financial details
Company Rating
-
Market Cap
49.98M
Income
-11.82M
Revenue
250K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-0.34
Forward P/E
-
PEG
0.04
P/S
20.03
P/B
0.28
P/C
-
P/FCF
-0.43
Quick Ratio
5.83
Current Ratio
6.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.57
EPS next Y
-
EPS next Q
-
EPS this Y
-90.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-46.28%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-7.55%
-
-
-
-
SMA20
3.85%
SMA50
103.23%
SMA100
125%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-84%
ROC
-0.95%
Gross Margin
100%
Oper. Margin
-5506%
Profit Margin
-4728%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.82-36.6
52W High
-93.9%
52W Low
-26.83%
RSI
58.85
Rel Volume
44.48
Avg Volume
197.7K
Volume
8.79M
Perf Week
19.95%
Perf Month
3.54%
Perf Quarter
212.95%
Perf Half Y
227.37%
-
-
-
-
Beta
1.575
-
-
Volatility
0.17%, 0.19%
Prev Close
4.52%
Price
2.195
Change
6.04%
Company Profile
- Volume Average 197.7K
- Market Capitalization 49.98M
- Employee 12
- CEO Mr. J. D. Finley
- Headquarters Carlsbad,CA,US
- IPO Date 2007-03-30
-
Website
https://www.palisadebio.com 
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
